Market: NMS |
Currency: USD
Address: 4870 Sadler Road
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
📈 Adial Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$54.17
-
Upside/Downside from Analyst Target:
23,298.13%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.040000 |
- |
2023-08-07 |
- |
Stock split |
|
Total Amount for 2023: $0.040000 |
📅 Earnings & EPS History for Adial Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 | -2 |
| 2025-08-13 | -4.5 |
| 2025-05-14 | -8.5 |
| 2025-03-04 | -3.75 |
| 2024-11-13 | -9.5 |
| 2024-08-13 | -14.75 |
| 2024-05-14 | -17.03 |
| 2024-04-01 | -9.25 |
| 2023-11-14 | -28.5 |
| 2023-08-21 | -33.25 |
| 2023-05-12 | -68.75 |
| 2023-03-30 | -68.75 |
| 2022-11-14 | -75 |
| 2022-08-15 | -100 |
| 2022-05-16 | -81.25 |
| 2022-03-28 | -175 |
| 2021-11-15 | -137.5 |
| 2021-08-12 | -156.25 |
| 2021-05-17 | -187.5 |
| 2021-03-22 | -156.25 |
| 2020-11-13 | -150 |
| 2020-08-13 | -100 |
| 2020-03-20 | -118.75 |
| 2019-11-14 | -106.25 |
| 2019-08-13 | -131.25 |
📰 Related News & Research
No related articles found for "adial pharmaceuticals".
